Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Allergan signs deal with Editas for gene-editing-based eye treatments

Published Tuesday March 14

Photo: Reuters

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.

The five eye programs include Editas’s lead drug, which is currently in pre-clinical development, to treat a rare, inherited eye disorder…

Article length: About 270 words.
Tags: Patent Deal
Read more at Reuters